详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Therapeutic efficacy of rare earth carbonate with chemoradiotherapy in late-stage non-small cell lung cancer: a cohort prospective study

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Earth Sciences, Kunming University of Science and Technology, Kunming, China. [2]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. [3]Department of Oncology, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China. [4]College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China. [5]Undergraduate Department, Taishan University, Taian, China. [6]School of Public Health, Nanchang University, Nanchang, China. [7]Institute of Medical Information/Library, Chinese Academy of Medical Sciences, Beijing, China. [8]Division of Sports Science & Physical Education, Tsinghua University, Beijing, China.

出处：

DOI：

ISSN：

关键词： concurrent chemoradiotherapy non-small cell lung cancer immune escape progression-free survival lung cancer prognostic factors

摘要：

To compare the therapeutic effects and adverse reactions of sterilizing rare earth carbonate combined with concurrent chemoradiotherapy and simple concurrent chemoradiotherapy in the treatment of late-stage non-small cell lung cancer (NSCLC), and to analyze the reasons for the differences.A total of 817 patients with pathologically diagnosed late-stage NSCLC from June 1, 2021 to December 30, 2022, in the affiliated hospital of Kunming University of Science and Technology, were selected. They were randomly divided into a control group of 394 people and an experimental group of 423 people. The control group was given concurrent chemoradiotherapy (cisplatin + etoposide), while the experimental group simultaneously took a low dose of sterilized rare earth carbonate (0.05mg/Kg). The χ² test and Fisher's test were used to compare the clinical pathological features, objective response rate (ORR), ECOG score, and adverse reactions of the two groups of patients, while survival analysis was used to compare the progression-free survival (PFS) of the two groups. Cox regression analysis was used to test factors related to prognosis.The differences in clinical pathological features between the two groups of patients were not statistically significant, with all P>0.05. The ORR of the control group was 45.18% (178/394), and the experimental group was 89.83% (380/423), with a statistically significant difference (P=0.001). After treatment, the ECOG score of the experimental group was lower than that of the control group, P<0.001. The adverse reaction grading of patients in both groups was below level 3 after treatment, and no treatment-related fatalities occurred. The risk of pulmonary infection and bone marrow suppression in the experimental group was lower than that in the control group.In late-stage NSCLC patients, compared with simple concurrent chemoradiotherapy, the combination of concurrent chemoradiotherapy and sterilizing rare earth carbonate can significantly improve the short-term therapeutic effect and prognosis of patients, with good safety.Copyright © 2023 Cao, Ye, Wu, Zhang, Gong, Chen, You, Shen, Qiang and Cao.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 2 区医学

小类 | 2 区内分泌学与代谢

最新[2023]版：

大类 | 2 区医学

小类 | 2 区内分泌学与代谢

第一作者：

第一作者机构： [1]Department of Earth Sciences, Kunming University of Science and Technology, Kunming, China. [2]Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

Therapeutic efficacy of rare earth carbonate with chemoradiotherapy in late-stage non-small cell lung cancer: a cohort prospective study

文献详情

相关文献